Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current eraAnand Patel, Olatoyosi Odenike, Raven Dean et al.|Blood Advances|2024Cited by 32
Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid TherapiesAnand Patel, Olatoyosi Odenike, James Yoon et al.|Blood|2022Cited by 6
Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasmsLeah Goldberg, Anand Patel, James Yoon et al.|Blood Neoplasia|2025Cited by 5
Targeted Therapy for MPNs: Going Beyond JAK InhibitorsEvan C. Chen, Anand Patel, Hannah Johnston|Current Hematologic Malignancy Reports|2023Cited by 2
Outcomes of Patients with <i>IDH1/2</i> Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH InhibitorsLeah Goldberg, Anand Patel, James Yoon et al.|Blood|2024Cited by 2